1. BMP7: In primary dopaminergic neuronal culture, BMP7 reduced MA mediated toxicity (i.e. decreased TH immunoreactivity and increasing TUNEL labeling). BMP7 also reduced MA mediated toxicity in vivo. Intra-cerebroventricular administration of BMP7 antagonized MA-induced changes in TH immunoreactivity in striatum and locomotor activity in mice. We found that intracerebroventricular administration of 9-cis-retinoic acid (9cRA) enhanced BMP7 mRNA expression, detected by RTPCR. Pretreatment with 9cRA attenuated the loss of TH immunoreactivity in striatum after high dose of MA administration. In stroke rats, pretreatment with 9cRA increased locomotor activity and attenuated neurological deficits 2 days after stroke. 9cRA also reduced cerebral infarction and TUNEL labeling. These protective responses were antagonized by BMP antagonist noggin given at one day after 9cRA injection. Taken together, our data suggest that 9cRA has protective effects and these effects involve BMPs. 2. MANF: We first examined the interaction of MANF and methamphetamine (MA) in primary ventral mesencephalic cultures containing dopaminergic neurons. Our preliminary data indicate that MANF attenuated MA toxicity in dopaminergic neurons in culture. We also found that MANF reduced ischemic brain injury and promoted behavioral recovery. Pre-stroke delivery of MANF protein, at a dose of 6 g, reduced cerebral infarction, suppressed DNA fragmentation, and facilitated motor recovery in stroke rats. Local administration of AAV-MANF enhanced MANF expression in neurons and glia in cerebral cortex. Pretreatment with AAV-MANF reduced the volume of cerebral infarction and facilitated behavioral recovery in stroke rats. Our data suggest that administration of either MANF protein or AAV-MANF reduces ischemic brain injury. 3. CDNF: We examined whether CDNF injections into striatum of C57/Bl6 mice have neuroprotective and neurorestorative properties for the nigrostriatal dopamine system after MPTP injections. We found that bilateral striatal CDNF injections, given 20-h before MPTP exposure, improved horizontal and vertical motor behavior when measured 2 weeks afterwards. In addition, CDNF pre-treatment increased tyrosine hydroxylase (TH)-immunoreactivity in the striatum and in the substantia nigra pars reticulata (SNpr), as well as number of TH-positive cells in substantia nigra pars compacta (SNpc). Post-treatment with CDNF, given 1 week after MPTP injections, increased horizontal and vertical behavior of mice. Furthermore, dopamine fiber densities in striatum and the number of TH positive cells in SNpc were increased after CDNF injections. We conclude that intrastriatal CDNF administration is both neuroprotective and neurorestorative for the nigrostriatal dopamine system in the MPTP model, which supports the development of CDNF-based treatment strategies for Parkinsons disease. 4. Nurr1: We found that METH binge exposure in adolescence led to greater damage in the nigrostrial dopaminergic system when mice were exposed to METH binge later in life, suggesting a long-term adverse effect on the dopaminergic system. Compared to naive mice that received METH binge treatment for the first time, mice pretreated with METH in adolescence showed a greater loss of tyrosine hydroxylase (TH) immunoreactivity in striatum, loss of THir fibers in the substantia nigra reticulata (SNr) as well as decreased dopamine transporter (DAT) level and compromised DA clearance in striatum. These effects were further exacerbated in Nurr1 heterozygous mice. Our data suggest that a prolonged adverse effect exists following adolescent METH binge exposure which may lead to greater damage to the dopaminergic system when exposed to repeated METH later in life. Furthermore, our data support that Nurr1 mutations or deficiency could be a potential genetic predisposition which may lead to higher vulnerability in some individuals.

Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2012
Total Cost
$546,539
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
Zip Code
Luo, Yu; Shen, Hui; Liu, Hua-Shan et al. (2013) CART peptide induces neuroregeneration in stroke rats. J Cereb Blood Flow Metab 33:300-10
Henderson, Mark J; Richie, Christopher T; Airavaara, Mikko et al. (2013) Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion and cell surface binding are modulated by KDEL receptors. J Biol Chem 288:4209-25
Li, Yazhou; Chigurupati, Srinivasulu; Holloway, Harold W et al. (2012) Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 7:e32008
Yu, Seong-Jin; Airavaara, Mikko; Shen, Hui et al. (2012) Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway. Psychopharmacology (Berl) 221:479-92
Liu, Hua-Shan; Shen, Hui; Harvey, Brandon K et al. (2011) Post-treatment with amphetamine enhances reinnervation of the ipsilateral side cortex in stroke rats. Neuroimage 56:280-9
Harvey, Brandon K; Airavaara, Mikko; Hinzman, Jason et al. (2011) Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One 6:e22135
Shen, Hui; Harvey, Brandon K; Chiang, Yung-Hsiao et al. (2011) Methamphetamine potentiates behavioral and electrochemical responses after mild traumatic brain injury in mice. Brain Res 1368:248-53
Airavaara, Mikko; Voutilainen, Merja H; Wang, Yun et al. (2011) WITHDRAWN: Neurorestoration. Parkinsonism Relat Disord :
Shen, H; Luo, Y; Yu, S-J et al. (2011) Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant mice. Neuroscience 194:170-80
Cadet, Jean Lud; Brannock, Christie; Krasnova, Irina N et al. (2010) Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats. PLoS One 5:e15643

Showing the most recent 10 out of 19 publications